When your patients are diagnosed with a rare cancer type, when chemotherapy doesn't work or when cancer comes back, OncoDEEP can help you unlock the molecular insights that you need to plan your treatment strategies.
Compared to single-gene tests, OncoDEEP is a comprehensive biomarker test that screens for a very wide range of cancer biomarkers in parallel. This 360-degree approach reduces the costs of testing and delivers faster results in the selection of appropriate cancer treatment options.
OncoDEEP is the most comprehensive biomarker test available on the market. The test targets cancer biomarkers carefully selected for their clinical relevance, and it offers a unique combination of analyses that proved to maximize the clinical benefits for cancer patients.
In one simple biomarker test and in less than two weeks, OncoDEEP can help you to:
Identify the cancer treatment options that match your patient's tumor profile;
Reveal early indication of treatment resistance and spare nonresponders the toxicity of a treatment with no therapeutic benefit;
Consider appropriate oncology clinical trials that are currently recruiting;
Understand why chemotherapy stopped working.
OncoDEEP: Turn deep insights into personalized treatment strategies
Precision medicine has changed the way cancer is treated. With OncoDEEP biomarker test, clinicians can obtain deep insights into a patient's solid tumor and receive a report with all the appropriate cancer treatment options, such as chemotherapy, immunotherapy, targeted therapy, hormonal therapy, and oncology clinical trials.
The role of fusion genes for cancer screening and therapy selection
With advances in precision medicine, there now exist therapies that target gene fusion in solid tumors. Unlike most common biomarkers, gene fusions are complex biomarkers that are visible at both DNA and RNA levels. Our Senior Scientist Support explains why it is so important to screen for fusion genes and what the methods available are.
We regularly run studies in order to evaluate the clinical impact of our comprehensive biomarker test in real life. Discover our key scientific publications published in peer-reviewed international journals.
Genomic Profiling for Patients with Solid Tumors: A Single-Institution Experience ... [READ MORE]
- Annals of Clinical Oncology
The clinical impact of using complex molecular profiling strategies in routine oncology practice ... [READ MORE]
Carcinomas of unknown primary are a diagnostic and therapeutic challenge for oncologists. They account for 3%–5% of newly diagnosed advanced malignancies, with chemotherapy as standard of care. By definition, patients diagnosed with CUP cancer have metastatic disease, but the specific site of the primary cancer is unknown. Consequently, traditional treatment approaches, which rely on the site of origin being known, are often ineffective.
At OncoDNA, we can help identify the cancer type of your patients by running a set of IHC tests based on ESMO guidelines. The technology has proven successful, with oncologists observing treatment response and prolonged overall survival rates in their CUP cancer patients.
While biomarker testing does not always succeed in identifying the primary origin of a cancer, OncoDEEP comprehensive biomarker test can help you identify cancer treatment options likely to improve clinical outcomes, deliver the right treatment at the right time and avoid your patient the toxicity of an ineffective standard chemotherapy.
Comprehensive biomarker testing - also known as comprehensive genomic profiling or genomic cancer test or molecular diagnostic test - is a next-generation sequencing (NGS) approach that uses a single assay to detect relevant cancer biomarkers, alterations in genes that are known to drive cancer growth, as established in guidelines and clinical trials, for therapy guidance. OncoDEEP goes one step further by integrating tumor-specific biomarker analyses to maximize the clinical benefit for the patients.
Combining different biomarker analyses is the key to maximize the clinical benefit for the patients. A study demonstrated the clinical utility of integrating DNA, RNA and proteins in one single biomarker test. The trial was led on 1,057 advanced cancer patients in 30 countries on 4 continents that had already experienced treatment failure(s).
The OncoDEEP comprehensive biomarker test combines NGS with IHC testing to screen for genomic alterations in the DNA and RNA (BRCA mutation, KRAS mutation, EGFR mutations, etc), genomic signatures (tumor mutational burden, homologous recombination deficiency and microsatellite instability testing) and protein biomarkers of response to targeted therapies, immunotherapy, hormonal therapy and chemotherapy. The technology is robust and accurate, and the genes of the panel were carefully selected based on their biological and therapeutical relevance.
Analyses of RNA genes enable the identification of gene fusion and unusual splicing variants that are present in solid tumors and that may predict a patient's sensivitity to targeted therapy or homorne therapy. An example is the targeted therapy "larotrectinib". A pan-cancer drug that targets abnormal TRK gene proteins in patients with NTRK fusion cancer.
The OncoDEEP panel includes 20 RNA genes (e.g. NTRK gene, FGFR gene, BRAF gene) that are associated with personalized medicines. Those personalized medicines can be a targeted therapy, a hormonal therapy, or an oncology clinical trial that is currently recruiting. We do not make any distinction between solid tumor types and we run RNA sequencing for all patient cases, be they diagnosed with a breast cancer, ovarian cancer, NSCLC, prostate cancer or a glioblastoma to name a few.
Comprehensive biomarker testing is recommended for adults with stage 3 cancer or stage 4 cancer with solid tumors - such as metastatic breast cancer, stage 4 lung cancer, stage 3 colon cancer, metastatic prostate cancer, stage 4 ovarian cancer - or for children with brain cancer. In case of cancer of unknown primary (CUP cancer), OncoDEEP can help decipher the primary origin of the tumor and guide clinicians towards approved therapies or drugs currently in development in oncology clinical trials.
OncoDEEP can be used at diagnosis or at disease progression to identify biomarker-matched targeted therapies or biomarker-stratified clinical trials. It can also provide physicians with extra therapeutic guidance when chemotherapy does not work; when new biomarkers are required for second-line treatment; when cancer comes back; or when patients are diagnosed with highly aggressive cancer or a rare cancer type like a cancer of unknow primary.
OncoDEEP can be performed on tissue biopsy, fine needle biopsy or bone marrow aspirate. The quality of laboratory test results is highly dependent on proper specimen collection and handling procedures. Our teams can guide you through our sample preparation protocol in case of any questions. All histologic samples will be reviewed by a pathologist after reception at OncoDNA.
The ISO 15189 (Medical laboratories-Requirements for quality and competence), CE-IVD (In vitro diagnostic devices complied to be sold in Europe), ISO 27001 (Information security management) and ISO 13485:2016 (Quality Management System) apply to our OncoDEEP comprehensive biomarker test.
Ordering a solution is very simple: Just log in to OncoSHARE and select the biomarker test(s) you are interested in. If you do not have a kit for the collection of the FFPE tissue sample, we will send you one.
You can order an OncoDEEP from anywhere in the world. In the United States, OncoDEEP can be used for academic projects only. The test cannot be used for molecular diagnostics yet.
After FFPE tissue sample processing and data interpretation, a comprehensive and interactive report will be made available for you on OncoSHARE, our secure clinical decision support software. It will help you select the most appropriate treatments based on the unique signature of your patient's tumor. You will also be able to share the report with your colleagues.
It takes about 10 working days from the FFPE tissue sample quality control check to reporting on our clinical decision support system.
Cannot find what you are looking for? Contact us! Our Scientific Support Teams are available to answer all your questions from Monday to Friday.